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MaBACKGROUND In pulmonary arterial hypertension (PAH), acute vasodilator response testing (AVT) is considered
important to identify adult patients with favorable prognosis using calcium-channel blocker (CCB) therapy. However, in
pediatric PAH, criteria used to identify acute responders and CCB use are insufﬁciently studied.
OBJECTIVES This study sought to describe current clinical practice of AVT and subsequent treatment decisions in
pediatric PAH.
METHODS From January 2008 to May 2013, 529 consecutive children with conﬁrmed pulmonary hypertension were
enrolled in an international registry. We analyzed those children with evaluable AVT.
RESULTS Of 382 children with evaluable AVT, 212 had idiopathic/familial PAH (IPAH/FPAH) and 105 had PAH associated
with congenital heart disease (PAH-CHD). In 70% of the patients, AVT was performed using inhaled nitric oxide; other
agents were used in the remaining patients. In IPAH/FPAH patients, 78 (37%) patients were acute responders according
to their physician, 62 (30%) according to REVEAL (Registry-to-Evaluate-Early-And-Long-term PAH disease
management)-pediatric criteria, and 32 (15%) according to Sitbon criteria. For PAH-CHD patients, the numbers of AVT
responders were 38 (36%), 14 (13%), and 7 (7%) respectively. Correlation between AVT responder status as judged by
the treating physician and by published response criteria was poor. Moreover, of the IPAH/FPAH patients judged by the
treating physician as acute responders, only 23% were treated with CCB without additional PAH-targeted therapy. The
Sitbon criteria selected patients with better prognosis who had excellent outcome when treated with CCB.
CONCLUSIONS The current practice of identifying responders to AVT and subsequent treatment with CCB therapy
demonstrated large discrepancies with current international guidelines. Also, in pediatric IPAH, the Sitbon criteria are
the criteria of choice to identify patients with excellent survival when treated with CCB therapy. (J Am Coll Cardiol
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AB BR E V I A T I O N S
AND ACRONYM S
AVT = acute vasodilator
response testing
CCB = calcium-channel blocker
CHD = congenital heart disease
iNO = inhaled nitric oxide
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1313P ulmonary arterial hypertension (PAH) is a se-vere disease in which pulmonary arteryremodeling leads to an increase in pulmonary
vascular resistance and pulmonary arterial pressure
eventually resulting in right ventricular failure and
death. Despite evolving treatment guidelines and
the availability of PAH-targeted therapies, PAH prog-




mPAP = mean pulmonary
arterial pressure
mSAP = mean systemic arterial
pressure
PAH = pulmonary arterial
hypertension
PH = pulmonary hypertension
PVRi = pulmonary vascular
resistance index
RHC = right heart
catheterization
WHO-FC = World Health
Organization functional classPulmonary hypertension (PH)–speciﬁc treatment
regimens can be divided into calcium-channel blockers
(CCB) and PAH-targeted therapy. A small subset of
idiopathic/familial PAH (IPAH/FPAH) patients have a
sustained favorable outcome when treated with CCB,
without the need for additional PAH-targeted therapy
(1,4–6). It is therefore of utmost importance to identify
patients who respond favorably to CCB therapy. Ac-
cording to both adult and pediatric treatment guide-
lines, acute vasodilator response testing (AVT)
identiﬁes these patients (7,8).
Currently, AVT is used for different purposes in
patients with PAH: 1) selecting IPAH/FPAH-patients
for CCB therapy; 2) assessing long-term prognosis;
and 3) assessing defect operability in children with
congenital heart disease (CHD) associated with PAH
(8,9). It is important to note that the AVT criteria used
for the ﬁrst 2 purposes will be discussed in this article
and that the proposed criteria are not designed nor
appropriate for assessing operability in CHD.
Over time, different AVT criteria have been pro-
posed to assess which patients should be treated with
CCB (2,4,5,9–14). Eventually these criteria evolved
into adult criteria proposed by Sitbon et al. that were
adopted by the American College of Cardiology
Foundation/American Heart Association (15) and
European Society of Cardiology guidelines (7) on PH.
For children with PAH, other criteria have been
proposed, most recently modiﬁed by the REVEAL
(Registry-to-Evaluate-Early-And-Long-term PAH dis-
ease management) registry investigators studying a
subcohort of childhood-onset PAH patients (2,5,7).
Adult IPAH/FPAH patients with an acute response
based on the Sitbon et al. (5) criteria have been shown
to respond well to CCB therapy with sustained
hemodynamic improvement and low World Health
Organization functional class (WHO-FC). In contrast,
less selective AVT criteria performed less well in
identifying adult patients with a long-term CCB
treatment response (5). For children with PAH, Yung
et al. (6) showed that responders, according to the
REVEAL-pediatric criteria, had favorable outcomes
when treated with CCB, although long-term CCB
treatment success rate was low and a way ofpredicting treatment success was not found.
Furthermore, there is no generally accepted
standard on how and with which agent to test
acute vasodilator response in children.
Therefore, more data on AVT and CCB ther-
apy in pediatric PAH are needed.
The purpose of this study was to evaluate
current clinical practice of AVT and subsequent





A center-based registry initiated January 31,
2008, the TOPP registry covers 31 centers in
19 countries (16). The TOPP registry collects
data on the assessment, treatment, and
follow-up of pediatric PH patients. Partici-
pating centers include consecutive patients
between 3 months and 18 years of age pre-
senting with PAH or with PH groups 3 to 5
(classiﬁed according to the 2003 Third World Pulmo-
nary Hypertension Symposium) and diagnosed on or
after January 1, 2001 (16).
Patients were eligible for TOPP inclusion when
meeting pre-speciﬁed hemodynamic criteria: mean
pulmonary arterial pressure (mPAP) of $25 mm Hg,
pulmonary vascular resistance index (PVRi) of $3
WU$m2, and a mean pulmonary capillary wedge
pressure of #12 mm Hg (17). Cardiac output was
determined either by thermodilution in the absence
of intra- or extra-cardiac shunts, or calculated by
Fick method using either measured oxygen con-
sumption provided by the treating physician or
assumed oxygen consumption, according to LaFarge
and Miettinen (18). Hemodynamic data of all included
patients were reviewed by the TOPP registry execu-
tive board members to conﬁrm diagnosis, leading to a
cohort of right heart catheterization (RHC) conﬁrmed
PH patients (PH-conﬁrmed).
For the current study, data from the May 2013 data
export were analyzed and all PH-conﬁrmed patients
(n ¼ 529) (Figure 1) were eligible for inclusion.
Patients in whom no AVT was performed at diag-
nostic RHC or the administered vasodilator during
AVT was considered inadequate (supplemental
oxygen concentration FiO2 <0.45) or unknown were
excluded from the analyses, as were patients with
incomplete pressure or ﬂow data at AVT.
For all included patients, the treating physicians
stated whether they considered the patient to be an
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1314acute vasodilator response at diagnosis, determined
post hoc by re-evaluating the diagnostic hemodynamic
data using the REVEAL-pediatric criteria proposed by
Barst et al. (2) and the Sitbon criteria (5), adopted by the
American College of Cardiology Foundation/American
Heart Association (15) and European Society of Cardi-
ology (7) PH guidelines (Table 1).
The proportion of AVT responders was analyzed
for patients with IPAH/FPAH separately from patients
in other diagnostic subgroups, because these acute
response criteria were primarily designed for IPAH/
FPAH patients and not validated for other diagnoses.
For IPAH/FPAH patients, patient characteristics,
hemodynamic proﬁle, and initial treatment of AVT
responders were compared to nonresponders. Treat-
ment was classiﬁed as CCB with or without additional
PAH-targeted therapy (CCB  PAH-targeted therapy),
PAH-targeted therapy (without CCB), or no PH-
speciﬁc therapy. Also, for the IPAH/FPAH patients,
patient characteristics, and hemodynamic proﬁles
were compared between those who did or did not
receive CCB.
STATISTICAL ANALYSES. Statistical comparisons
were made using Student t test, Mann-Whitney U
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atients whose pulmonary hypertension (PH) could not be hemody-
patients in whom either no acute vasodilator response testing (AVT)
AVT agent was not adequate (unknown or low-dose oxygen), or data
r ﬂow were not complete were excluded. IPAH/FPAH ¼ idiopathic/
rterial hypertension; PAH-CHD ¼ pulmonary arterial hypertension
enital heart disease.between the acute response at the discretion of the
treating physician versus by criteria were tested using
the McNemar test. Transplant-free survival was
analyzed from diagnosis to death/lung trans-
plantation or last follow-up visit using Kaplan-Meier
curves and log-rank tests. Analyses were performed
using SPSS 18.0 (IBM, Armonk, New York). The level
of signiﬁcance was deﬁned as p < 0.05, 2-sided.
RESULTS
In May 2013, the TOPP registry included 529 pediatric
patients with conﬁrmed PH. We excluded 147 patients
without complete AVT, which included 64 of 276
IPAH/FPAH patients (23%), leaving 382 patients
included in the current study (Figure 1). Of these pa-
tients, 212 had IPAH/FPAH, 105 PAH-CHD, and 65
another form of PH (associated PAH excluding CHD,
PH group 3, or PH group 4 to 5). In one-half of the
children, heart catheterization was performed under
general anesthesia; in the other one-half, procedural
sedation was used. The majority (70%) of the
included patients had AVT with inhaled nitric oxide
(iNO) with or without additional O2. The other pa-
tients were tested with various other agents (Table 2
for numbers per diagnosis).
IPAH/FPAH PATIENTS. Of the IPAH/FPAH patients,
78 of 212 (37%) were considered acute responders
by their treating physician. According to the
REVEAL-pediatric criteria and the Sitbon criteria,
these numbers were 62 (30%) and 32 (15%), respec-
tively (Central Illustration). There was a notable
discrepancy between the responder status assessed by
the treating physician and that assessed by reported
criteria (McNemar p ¼ 0.050 and p < 0.001 for the
REVEAL-pediatric and Sitbon criteria, respectively)
(Table 3). Speciﬁcally, a high number of patients were
regarded responders by their physicians, but not ac-
cording to the criteria (29 for the REVEAL-pediatric
criteria, 49 for the Sitbon criteria). Of the patients
regarded as nonresponders by their physician, 15 were
responders according to REVEAL-pediatric criteria
and 3 per the Sitbon criteria.
All 32 Sitbon responders were also REVEAL-
pediatric responders (Table 3). The remaining 30
REVEAL registry responders showed either a decrease
of cardiac index (n ¼ 16) at AVT or a >20% drop in
mPAP that, however, remained >40 mm Hg (n ¼ 18)
or was <10 mm Hg (n ¼ 6), which precluded acute
responder status by Sitbon criteria. Of the 32 patients
who reached a normal mPAP at AVT (<25 mm Hg,
range 18 mm Hg to 24 mm Hg), 7 had a decrease of
mPAP <10 mm Hg, precluding them from being a
Sitbon responder.
TABLE 1 Acute Vasodilator Response Criteria
Physician’s Judgment
 An acute response at the discretion of the treating physician
REVEAL-pediatric criteria by Barst et al. (2)
 A decrease in mPAP of $20%
 And an unchanged, increased, or less than 10% decreased
cardiac index
 And a decreased or unchanged pulmonary-to-systemic vascular
resistance ratio
Adult criteria by Sitbon et al. (5,7)
 Reduction of mPAP of $10 mm Hg
 To reach an absolute value of mPAP #40 mm Hg
 And an increased or unchanged cardiac output
mPAP ¼ mean pulmonary arterial pressure; REVEAL ¼ Registry to Evaluate Early
And Long-term PAH disease management.
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1315In IPAH/FPAH patients, acute responders accord-
ing to the REVEAL-pediatric or Sitbon criteria were
more often female than male than nonresponders.
There were signiﬁcantly more responders in the pa-
tients tested under procedural sedation compared
to patients under general anesthesia. No differences
in age, weight, height, body mass index, occurrence
of (near-)syncope or WHO-FC were demonstrated
between responders and nonresponders. The pro-
portion of acute responders was not associated with
age at diagnostic RHC. Acute responders compared to






Age at diagnosis, yrs 7.8 (4.2–13.0) 6.1 (2.3–11.
Female 133 (62.7) 60 (57.1)
Incident patients 106 (50) 54 (51.4)
WHO functional class
I 28 (13.2) 15 (14.3)
II 89 (42.0) 52 (49.5)
III 73 (34.4) 37 (35.2)
IV 22 (10.4) 1 (1.0)
Sedation method at HC
General anesthesia 101 (47.9) 56 (53.8)
Procedural sedation 110 (52.1) 48 (46.2)
Baseline mPAP, mm Hg 59  18 58  20
Baseline mRAP, mm Hg 7  4 7  4
Baseline PVRi, WU$m2 15.9 (10.5–22.6) 11.9 (8.1–20
Baseline cardiac index, l/min/m2 3.1 (2.4–4.1) 3.3 (2.5–3.9
AVT agent
iNO (and O2) 152 (71.7) 64 (61.0)
Other* 60 (28.3) 41 (39.0)
Values are median (interquartile range), n (%), or mean  SD. *Other agents included a
aPAH excl. CHD ¼ associated pulmonary arterial hypertension excluding congenital hea
FPAH ¼ idiopathic/familial pulmonary arterial hypertension; iNO ¼ inhaled nitric oxide
associated with congenital heart disease; PH ¼ pulmonary hypertension; PVRi ¼ pulmon
other abbreviations as in Table 1.REVEAL-pediatric criteria, or physician’s judgment)
had a more favorable hemodynamic proﬁle, charac-
terized by lower mPAP, mean right atrial pressure,
PVRi, mPAP/mean systemic arterial pressure (mSAP),
and pulmonary-to-systemic vascular resistance ratio
both at baseline and at AVT, and a higher cardiac in-
dex at AVT (Table 4).
Acute responders were more often treated with
CCB than nonresponders. However, of the 78 patients
judged by their physician to be responders, only 18
(23%) were treated with CCB monotherapy and 11
(14%) received CCB with additional PAH-targeted
therapy (Figure 2). Three of the responders not
treated with CCB were <1 year of age and an addi-
tional 9 were in WHO-FC IV, which might explain why
no CCB was initiated, leaving 37 patients (59%) not
treated with CCB while they were >1 year of age, in
WHO-FC I to III, and judged to be an acute responder.
IPAH/FPAH patients who were prescribed CCB had a
lower mPAP, mean right atrial pressure, PVRi, PVRi/
systemic vascular resistance index and mPAP/mSAP,
both at baseline and at AVT, and a higher cardiac
index at AVT, compared to those who did not receive
CCB (Table 5).
Median follow-up was 3.5 years (1.7 to 5.9 years).
Acute responders, as judged by the treating




PH Groups 4 and 5
(n ¼ 6)
9) 10.8 (7.2–14.1) 3.7 (1.4–9.7) 13.3 (6.1–13.6)
11 (52.4) 23 (60.5) 2 (33.3)
10 (47.6) 17 (44.7) 4 (66.7)
3 (14.3) 6 (15.8) 1 (16.7)
8 (38.1) 19 (50.0) 2 (33.3)
6 (28.6) 12 (31.6) 3 (50.0)
4 (19.0) 1 (2.6)
12 (57.1) 22 (57.9) 2 (33.3)
9 (42.9) 16 (42.1) 4 (66.7)
50  15 45  15 60  10
7  3 7  3 8  3
.3) 12.5 (8.6–18.3) 9.0 (6.4–11.5) 17.3 (13.2–24.0)
) 3.3 (3.0–4.0) 3.3 (2.8–4.6) 3.4 (1.8–4.1)
15 (71.4) 32 (84.2) 3 (50.0)
6 (28.6) 6 (15.8) 3 (50.0)
denosine, diltiazem, epoprostenol, iloprost, oxygen, and sildenaﬁl.
rt disease; AVT ¼ acute vasodilator response testing; HC ¼ heart catheterization; IPAH/
; mRAP ¼ mean right atrial pressure; PAH-CHD ¼ pulmonary arterial hypertension
ary vascular resistance index; WHO ¼ World Health Organization; WU ¼ Woods units;
CENTRAL ILLUSTRATION Acute Vasodilator Response in Pediatric PAH: Number of Acute Responders
A
B
Douwes, J.M. et al. J Am Coll Cardiol. 2016; 67(11):1312–23.
Continued on the next page
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TABLE 3 Crosstab of Acute Vasodilator Response Criteria
IPAH/FPAH (n ¼ 212) Responder
REVEAL-Pediatric
Criteria Sitbon Criteria
Yes No Yes No
Physician’s judgment Yes 47 (22.9) 29 (14.1) 29 (13.7) 49 (23.1)
No 15 (7.3) 114 (55.6) 3 (1.4) 131 (61.8)
REVEAL-pediatric criteria Yes 32 (15.6) 30 (14.6)
No — 143 (69.8)
Values are n (%).
IPAH/FPAH ¼ idiopathic/familial pulmonary arterial hypertension; REVEAL ¼ Registry to Evaluate Early And
Long-term PAH disease management.
J A C C V O L . 6 7 , N O . 1 1 , 2 0 1 6 Douwes et al.
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1317survival, compared to nonresponders (Figure 3A). In a
second survival analysis (Figure 3B), the Sitbon
responders (n ¼ 32) were compared to the non-Sitbon
REVEAL responders (n ¼ 30) and the nonresponders.
Sitbon responders had better transplant-free survival
compared to all other IPAH/HPAH patients. In con-
trast, the transplant-free survival of the 30 REVEAL
registry responders who were not Sitbon responders
was comparable to that of the nonresponders.
In order to analyze the beneﬁt of CCB in acute re-
sponders, we compared the survival of patients on CCB
(whether in combination with [] PAH-targeted ther-
apy) with patients on PAH-targeted therapy (without
CCB). Within the group of children judged to be re-
sponders by their physicians, no better transplant-free
survival could be demonstrated in children treated
with CCB compared to those receiving only PAH-
targeted therapy (without CCB) (Figure 4A). In
contrast, acute responders according to the Sitbon
criteria treated with CCB  PAH-targeted therapy
(n ¼ 20) had an excellent 100% survival, which seems
better than acute responders on only PAH-targeted
therapy (without CCB), although this difference did
not reach statistical signiﬁcance (Figure 4B). Also,
Sitbon responders on CBB monotherapy (n ¼ 15) had a
100% survival. Finally, REVEAL registry responders
who were not Sitbon responders treated with CCB had
comparable survival to those treated with only PAH-
targeted therapy (without CCB) (Figure 4C).
NON-IPAH/FPAH PATIENTS. The response-criteria
used here were neither designed nor appropriate for
patients with other forms of PAH than IPAH/HPAH.
Only for epidemiological comparison, we report the
prevalence of acute responders in other forms of PH
within the TOPP registry. Thirty-six percent of
PAH-CHD patients were regarded by their physicians
to be acute responders, which was comparable to the
IPAH/FPAH group (37%). The percentages of re-
sponders according to the REVEAL-pediatric criteria
(13%) and Sitbon criteria (7%) in PAH-CHD patients
were signiﬁcantly lower compared to pediatric
IPAH/FPAH patients (p ¼ 0.001 and p ¼ 0.32,
respectively). Within the PAH-CHD children, no sta-
tistically signiﬁcant difference in percentage of acute
responders could be demonstrated between those
with repaired or unrepaired (including partiallyDifferences in acute vasodilator response testing are noted among (A) res
subgroups of patients with pulmonary arterial hypertension associated wit
(including partially repaired) shunt. aPAH excl. CHD ¼ associated pulmon
FPAH ¼ idiopathic/familial pulmonary arterial hypertension; PH ¼ pulmon
shunt not included because n ¼ 1.
CENTRAL ILLUSTRATIONrepaired) shunts (Central Illustration). The percentage
of patients who were acute responders in the associ-
ated PAH excluding CHD group did not statistically
differ from the IPAH/FPAH group for all 3 criteria
(Central Illustration). In patients with PH due to res-
piratory disease, the percentages of responders ac-
cording to the treating physician seemed larger,
whereas the percentage of acute responder according
to the REVEAL-pediatric and Sitbon criteria seemed
lower compared to the pediatric IPAH/FPAH patients
(Central Illustration). However, no statistically signif-
icant differences could be demonstrated in these last
comparisons.
DISCUSSION
This study, using data from the worldwide TOPP
registry, provided an overview of clinical practice of
AVT in pediatric PH between 2001 and 2013. In the
reported cohort, AVT was not performed or inade-
quately performed in 23% of children with IPAH/
FPAH, although international treatment guidelines
since 2009 dictate AVT in IPAH/FPAH patients to
determine whether treatment with CCB therapy is
warranted. Furthermore, there are substantial dis-
crepancies between the presence of an acute response
as judged by the treating physician versus assessed by
reported AVT criteria. In clinical practice, a variety of
vasodilating agents was used to perform AVT. We
concluded that the reported pediatric clinical practice
is not congruent with current diagnosis and treat-
ment guidelines for PAH based on international
consensus regarding the selection of patients inponders separated for the different criteria and diagnosis as well as (B)
h congenital heart disease (PAH-CHD) with a repaired versus unrepaired
ary arterial hypertension excluding congenital heart disease; IPAH/
ary hypertension. *Refers to PAH-CHD subgroups. †PAH-CHD never
TABLE 4 Characteristics of Acute Vasodilator Responders Versus Nonresponders







p ValueYes No Yes No Yes No
Age at diagnosis, yrs 7.1 (4.2–12.1) 8.1 (4.2–13.4) 0.187 7.3 (4.2–13.0) 8.0 (4.3–13.1) 0.789 8.5 (4.7–12.8) 7.4 (4.0–13.2) 0.731
Female 53 (67.9) 80 (59.7) 0.231 47 (75.8) 81 (56.6) 0.009 28 (87.5) 105 (58.3) 0.002
Incident patients 33 (42.3) 73 (54.5) 0.087 35 (56.5) 67 (46.9) 0.207 17 (53.1) 89 (49.4) 0.701
WHO functional class
I 13 (16.7) 15 (11.2) 0.314 7 (11.3) 20 (14.0) 0.407 2 (6.3) 26 (14.4) 0.620
II 36 (46.2) 53 (39.6) 27 (43.5) 58 (40.6) 17 (53.1) 72 (40.0)
III 16 (20.5) 57 (42.5) 16 (25.8) 55 (38.5) 7 (21.9) 66 (36.7)
IV 13 (16.7) 9 (6.7) 12 (19.4) 10 (7.0) 6 (18.8) 16 (8.9)
Sedation method at HC
General anesthesia 29 (28.7) 72 (71.3) 0.017 23 (24.2) 72 (75.8) 0.097 8 (7.9) 93 (92.1) 0.005
Procedural sedation 49 (44.5) 61 (55.5) 38 (34.9) 71 (65.1) 24 (21.8) 86 (78.2)
Baseline mPAP, mm Hg 56  16 62  19 0.018 54  16 62  19 0.002 49  13 61  18 <0.001
AVT mPAP, mm Hg 37  17 56  19 <0.001 33  12 56  19 <0.001 27  8 53  19 <0.001
Baseline mRAP, mm Hg 6  3 8  4 0.001 6  4 7  4 0.002 5  3 7  4 <0.001
AVT mRAP, mm Hg 6  3 8  4 0.002 6  3 8  4 <0.001 5  3 7  4 <0.001
Baseline PVRi, WU$m2 13.5 (8.6–19.5) 17.3 (11.3–24.2) 0.007 12.7 (7.9–18.9) 16.7 (12.1–24.2) 0.002 12.9 (8.0–18.5) 16.3 (10.9–23.9) 0.006
AVT PVRi 6.0 (4.0–10.6) 15.2 (8.7–22.4) <0.001 4.5 (3.6–9.1) 14.8 (8.7–22.3) <0.001 4.2 (3.1–5.9) 12.6 (7.4–20.0) <0.001
Baseline cardiac index, l/min/m2 3.3 (2.8–4.3) 2.9 (2.2–3.8) 0.018 3.2 (2.7–4.4) 2.9 (2.4–4.0) 0.082 3.2 (2.8–4.4) 3.0 (2.4–4.0) 0.251
AVT cardiac index, l/min/m2 3.6 (2.9–4.5) 3.1 (2.3–4.1) 0.003 3.8 (3.0–5.0) 3.1 (2.3–3.9) <0.001 4.2 (3.4–5.1) 3.1 (2.4–4.0) <0.001
Baseline PVRi/SVRi 0.8 (0.6–0.9) 0.9 (0.7–1.2) 0.004 0.7 (0.5–0.9) 0.9 (0.7–1.1) 0.001 0.7 (0.5–0.8) 0.9 (0.7–1.1) <0.001
AVT PVRi/SVRi 0.4 (0.2–0.6) 0.7 (0.5–1.0) <0.001 0.4 (0.2–0.5) 0.7 (0.5–1.0) <0.001 0.3 (0.2–0.4) 0.7 (0.4–1.0) <0.001
Baseline mPAP/mSAP 0.8 (0.6–1.0) 0.9 (0.7–1.1) 0.007 0.8 (0.6–1.0) 0.9 (0.7–1.1) 0.004 0.7 (0.6–0.9) 0.9 (0.7–1.1) <0.001
AVT mPAP/mSAP 0.5 (0.3–0.7) 0.8 (0.6–1.0) <0.001 0.4 (0.3–0.6) 0.8 (0.6–1.0) <0.001 0.4 (0.3–0.5) 0.7 (0.5–1.0) <0.001
AVT agent
iNO (and O2) 50 (64.1) 102 (76.1) 0.061 47 (75.8) 102 (71.3) 0.509 23 (71.9) 129 (71.7) 0.981
Other 28 (35.9) 32 (23.9) 15 (24.2) 41 (28.7) 9 (28.1) 51 (28.3)
Values are median (interquartile range), n (%), or mean  SD.
mSAP ¼ mean systemic arterial pressure; SVRi ¼ systemic vascular resistance index; other abbreviations as in Tables 1 and 2.
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1318whom to perform an AVT, the agent to use for this
test, and the criteria used to determine the response
(7,8). There is a need for improvement and consis-
tency. The data of our current study may help to
achieve evidence-based recommendations (8).
Compared to the REVEAL-pediatric criteria, the
Sitbon criteria are the more selective. It has been
insufﬁciently clear whether the use of more selective
criteria in pediatric patients would lead either to a
more accurate selection of children who will beneﬁt
from CCB therapy and a better prognostic value or to
an unjustiﬁed exclusion of children who would be
identiﬁed with less strict criteria and who might also
beneﬁt from CCB therapy. In the current study, we
distinguished 3 groups of patients: 1) Sitbon re-
sponders (all of whom also appeared to be REVEAL
registry responders); 2) REVEAL registry responders
who were not Sitbon responders; and 3) non-
responders for both criteria. Transplant-free survival
of Sitbon responders was superior compared to
Sitbon nonresponders. Furthermore, children with
IPAH/FPAH who were Sitbon responders hadexcellent transplant-free survival when initially
treated with CCB. In contrast, acute responders ac-
cording to the less strict REVEAL-pediatric criteria,
who had not met the Sitbon criteria, had a transplant-
free survival similar to that of nonresponders. Of
these REVEAL registry responders not fulﬁlling Sit-
bon criteria, the children treated with CCB, whether
in combination with PAH-targeted therapy, had
comparable outcomes to those treated with only PAH-
targeted therapy. These data strongly suggest supe-
riority of the Sitbon criteria over the REVEAL-
pediatric criteria in identifying pediatric patients
with improved survival who will beneﬁt from CCB
therapy. Whereas children identiﬁed by only
REVEAL-pediatric criteria seem to have no better
outcome compared to nonresponders and no beneﬁt
from CCB therapy. A previous study by Yung et al.
indeed showed that the success rate of long-term CCB
therapy was relatively low in children with IPAH/
FPAH selected with the less strict REVEAL-pediatric
criteria (6). This followed data from adult PAH pa-
tients that showed the Sitbon criteria were superior to


























Initial treatment of acute vasodilator responders versus nonresponders in pediatric IPAH/FPAH patients varied depending on the acute
vasodilator response criteria. CCB ¼ calcium-channel blocker; other abbreviations as in Figure 1.
TABLE 5 Patient Characteristics Stratiﬁed for Therapy







(n ¼ 18) p Value*
Age at diagnosis, yrs 7.3 (4.6–12.9) 8.0 (3.9–13.2) 6.0 (4.2–13.1) 0.833
Female 26 (83.9) 94 (57.7) 13 (72.2) 0.008
Incident patients 14 (45.2) 82 (50.3) 10 (55.6) 0.560
WHO functional class
I 3 (9.7) 19 (11.7) 6 (33.3) 0.280
II 18 (58.1) 67 (41.1) 4 (22.2)
III 7 (22.6) 59 (36.2) 7 (38.9)
IV 3 (9.7) 18 (11.0) 1 (5.6)
WHO functional class
I and II 21 (67.7) 86 (52.8) 10 (55.6) 0.128
III and IV 10 (32.3) 77 (47.2) 8 (44.4)
6-min walking distance, min 414  128 397  127 358  104 0.557
Baseline mPAP, mm Hg 50  16 61  18 62  18 0.002
Baseline mRAP, mm Hg 5  3 7  4 8  4 <0.001
Baseline PVRi, WU$m2 13.0 (7.4–18.6) 15.9 (10.9–22.9) 21.3 (8.0–26.5) 0.014
Baseline cardiac index, l/min/m2 3.3 (2.9–4.3) 2.9 (2.4–4.0) 3.0 (2.0–4.0) 0.133
Baseline PVRi/SVRi 0.6 (0.4–0.8) 0.9 (0.7–1.1) 0.8 (0.7–1.1) <0.001
Baseline mPAP/mSAP 0.7 (0.5–0.8) 0.9 (0.7–1.1) 0.9 (0.7–1.1) <0.001
AVT mPAP, mm Hg 29  14 52  19 53  20 <0.001
AVT mRAP, mm Hg 5  4 7  4 8  3 0.003
AVT PVRi, WU$m2 4.1 (3.2–5.9) 12.4 (7.0–19.7) 13.6 (8.2–22.9) <0.001
AVT cardiac index, l/min/m2 4.1 (3.4–5.1) 3.1 (2.4–4.1) 3.1 (2.4–4.1) <0.001
AVT PVRi/SVRi 0.3 (0.2–0.4) 0.7 (0.4–1.0) 0.6 (0.4–0.9) <0.001
AVT mPAP/mSAP 0.3 (0.3–0.5) 0.7 (0.5–1.0) 0.8 (0.5–1.1) <0.001
Values are median (interquartile range), n (%), or mean  SD. *The p value of patients on CCB  PAH-targeted
therapy (the CCB monotherapy group combined with the CCB and PAH-targeted therapy group) versus the other
patients.
CCB ¼ calcium-channel blocker; other abbreviations as in Tables 1, 2, and 4.
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1319less strict criteria in selecting patients who will have a
sustained response to CCB therapy (5). In summary,
the current data suggest that the use of Sitbon criteria
is preferred, not only in adults but also in children
with IPAH/FPAH, when selecting patients for CCB
therapy.
It has been questioned whether the Sitbon criteria,
with its required absolute pulmonary arterial pres-
sure reduction, are applicable in young children. Ac-
cording to current guidelines, the deﬁnition of PH is
independent of age and requires an absolute mPAP
value >25 mm Hg (8). Infants may have relatively
lower values of baseline mPAP and may reach normal
mPAP values (<25 mm Hg) during AVT but without an
absolute decrease of 10 mm Hg. The current data
showed that this occurred in 7 of 212 IPAH/FPAH pa-
tients (3%). The prognosis of this small subgroup of
patients is indeed insufﬁciently deﬁned. However,
the small number of children in whom this applies
does not preclude using the Sitbon criteria in pedi-
atric PAH.
Interestingly, acute response to AVT by the treat-
ing physician’s judgment seemed to perform well in
differentiating patients with better versus worse
outcome. This might be explained by the physician
involving additional clinical parameters to judge a
patient’s responder status and make treatment
choices. In the current study, this is supported by the
observation that physician-identiﬁed responders had
a more favorable baseline hemodynamic proﬁle.
Therefore, acute response, as judged by the treating
physician using a broad array of clinical data, may be
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Patient survival was stratiﬁed for acute response status according to (A) physician’s judgment of responders (yes) versus nonresponders
(no), and (B) the different acute vasodilator response testing (AVT) criteria: Sitbon responders (SR); REVEAL (Registry-to-Evaluate-Early-
And-Long-term PAH disease management) registry responders who were not Sitbon responders (RR); and nonresponders according to both
criteria (NR). *Comparison of SR versus all other patients (RR and NR): p ¼ 0.058.
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1320associated with favorable prognosis. However, phy-
sician’s judgment did not perform as well as the Sit-
bon criteria in identifying patients who beneﬁted
from CCB therapy.
It has been postulated previously that children
more often exhibit an AVT response than adult pa-
tients with IPAH/FPAH, possibly due to younger age
(11,19). However, different criteria for acute re-
sponders that have historically been used in children
and adult patients might have contributed to this
assumed difference between pediatric and adult PAH
(9). The AVT criteria, proposed for children with
IPAH/FPAH, have gradually changed over time,
leading to a range in reported percentages of re-
sponders in pediatric IPAH/FPAH from 13% to 56%
(2,4,6,9,11). Using the REVEAL-pediatric criteria, we
found that 30% of children with IPAH/FPAH qualiﬁed
as acute responders. However, using the Sitbon
criteria, only one-half of these children qualiﬁed as
acute responders, which is comparable to percentages
reported in adults with IPAH/FPAH using these same
criteria (5% to 17%) (1,2,5,9,20,21). Moreover, in the
current cohort, we could not demonstrate a correla-
tion between age and acute responder status. The
current data therefore conﬁrmed the hypothesis that
reported differences between children and adults inthe proportion of acute responders can be attributed
to historic use of less strict AVT criteria in the pedi-
atric group, instead of a previously suggested corre-
lation between age and the presence of an acute
response in children (9).
In most patients in this study, iNO with or without
additional O2 was used to perform AVT. Available
data suggest that nitric oxide is a potent, safe, and
short-acting acute vasodilating agent in this setting.
Combining iNO with oxygen seems even more potent
(22–26). Other agents, such as iloprost and treprosti-
nil, may be equally potent (24–26). Comparative data
regarding the best agent or combination of agents to
identify not only an acute response but those patients
who respond well to long-term CCB therapy is lack-
ing. Nevertheless, use of iNO is currently recom-
mended in the guidelines for adult patients with PAH;
it is the most frequently used agent and has been
proven potent and safe in children, too (7,8). There-
fore, we also recommend iNO as the agent of choice, if
available, to perform AVT in pediatric PAH. The value
of additional pulmonary vasodilator response to
other or multiple agents for AVT remains to be
elucidated (27).
The current study revealed that patients undergo-
ing heart catheterization under procedural sedation
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Acute responders determined by (A) physician’s judgment, (B) Sitbon criteria (SR), or (C) REVEAL (Registry-to-Evaluate-Early-And-Long-term
PAH disease management)-pediatric criteria (RR). Only Sitbon Responders tended to survive longer over time when on CCB therapy
PAH-targeted therapy (CCBþ) versus only PAH-targeted therapy without CCB (CCB). Abbreviations as in Figures 1 to 3.
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1321more often showed an acute response than patients
under general anesthesia. It is speculative whether
this might be related to pulmonary vasodilating
properties of certain anesthetic agents or to the
maintenance of sympathetic activation during proce-
dural sedation. This ﬁnding requires further investi-
gation because they may directly affect the deﬁnition
and interpretation of acute response in pediatric PAH.
In patients with IPAH/FPAH, current treatment
guidelines propose to initiate treatment with CCB
when acute response can be achieved and the patientis not in WHO-FC IV, whereas PAH-targeted therapy
is advised when an acute response cannot be ach-
ieved. However, in the studied pediatric cohort, the
majority of patients considered acute responders
by their treating physician were not treated with
CCB therapy. Currently it is advised not to treat
children <1 year of age with CCB because of potential
negative inotropic effects (8), which may also disin-
cline physicians from treating patients with right
ventricular failure or in high WHO-FC (IV) with CCB,
as proposed by the adult treatment algorithm for
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: The
proportion of children with IPAH/FPAH who respond
to AVT is similar to that in adult IPAH/FPAH patients.
COMPETENCY IN MEDICAL KNOWLEDGE 2: For
children with IPAH/FPAH, the Sitbon criteria are the
criteria of choice to identify acute vasodilator re-
sponders who show a sustained beneﬁcial response to
CCB therapy.
TRANSLATIONAL OUTLOOK: Further implement-
ing current recommendations for AVT in pediatric
pulmonary hypertension centers will help improve the
selection of patients who will beneﬁt from CCB ther-
apy, which will improve patient outcome.
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1322PAH (7). In our study, however, these considerations
insufﬁciently explained the large number of patients
considered acute responders by their physician left
untreated with CCB therapy.
Compared to those who did not receive CCBs, pa-
tients treated with CCB therapy appeared to have a
better baseline hemodynamic proﬁle, a factor that
may have affected the decision to use CCB therapy.
This treatment decision, however, did not adhere to
current treatment guidelines. Children who show an
acute response at AVT have a favorable outcome
when treated with CCB; therefore, withholding this
treatment may not be in their best interest (1).
The percentage of AVT responders differed in
patients with other types of PAH than IPAH/FPAH.
PAH-CHD patients showed a lower percentage of
acute responders, regardless of the presence of a
repaired or unrepaired shunt. It is important to note
that the described AVT criteria were designed spe-
ciﬁcally to identify IPAH/FPAH patients who will
beneﬁt from CCB therapy and explicitly not for
patients with other forms of PAH. Both the Sitbon and
REVEAL-pediatric criteria require a signiﬁcant drop in
mPAP. It should be emphasized that in patients with a
nonrestrictive shunt defect at post-tricuspid level,
the mPAP equals mSAP and therefore mPAP can only
decrease substantially when the systemic arterial
pressure drops as well. Thus mPAP at AVT will not
represent a pulmonary vasodilator response, pre-
cluding the use of the AVT criteria described in this
report. It should further be emphasized that AVT is
also used to assess reversibility of PAH-CHD and
operability of congenital heart defects (28); however,
the criteria discussed in the current manuscript are
not suitable for this purpose.
STUDY LIMITATIONS. The TOPP registry is a pro-
spective observational international disease registry
with associated limitations. Because of the registry’s
observational nature, no standardized AVT protocol
was prescribed nor the use of predeﬁned response
criteria or treatment strategies. Baseline hemody-
namic measurements and AVT tests were performed
using different protocols, including variation in
baseline conditions and used acute vasodilator
agents. The data did not allow us to investigate
whether patients would have a more pronounced
acute response with other or additional vasodilating
agents. Only CCB therapy at diagnosis could be
analyzed; no data were available on the course of
treatment after initiation. Furthermore, not all acute
responders were treated with CCB, prohibiting more
deﬁnitive statements on which criteria perform best
in selecting patients who will respond well to CCB.
However, with its large sample size from a real-worldpopulation and its global generalizability, the TOPP
registry is unique in providing important insights on
current practice of AVT, subsequent treatment
decisions, and outcome in children with PAH.
CONCLUSIONS
The proportion of acute pulmonary vasodilator re-
sponders in children with IPAH/FPAH, using the
Sitbon criteria for acute response, was similar to that
reported in adults with IPAH/FPAH and appeared
unrelated to age. From a registry evaluating AVT in
children with IPAH/FPAH from 2001 to 2013, the
practice of identifying acute responders to AVT in
children with IPAH/FPAH was widely variant and
inconsistent with current internationally recom-
mended diagnostic algorithms for both adult and
pediatric patients. Furthermore, in reported clinical
practice, the majority of children with IPAH/FPAH,
classiﬁed as acute responders, were not treated with
CCB therapy. The current study suggested that, as in
adult IPAH/FPAH, the Sitbon criteria are the criteria
of choice in pediatric IPAH/FPAH to identify children
who will show sustained beneﬁt from CCB therapy. It
is advised to closely monitor acute responders treated
with CCB therapy during follow-up so that initiation
of PAH-targeted therapy is not delayed in case of CCB
treatment failure.
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